Research progress in the benefit of sodium-glucose co-transporter 2 inhibitors in the treatment of heart failure

VernacularTitle:钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中获益的研究进展
Author: Jiaojiao GUO ¹ ; Kaizheng GONG
Author Information

1. 扬州大学医学院，扬州　225000
Keywords: Heart failure; Sodium-glucose co-transporter 2; Inhibitor
From: Journal of Chinese Physician 2022;24(1):149-152
CountryChina
Language:Chinese
Abstract: Heart failure is one of the two major problems in cardiovascular field in this century. Although the treatment of heart failure has made great progress, but the prognosis of heart failure is poor, Standardized drug treatment is still one of the most important and preferred methods for the treatment of heart failure. Heart failure is one of the serious vascular complications of diabetes, which affects the prognosis of diabetes. In recent years, studies have found that the new hypoglycemic drug sodium-glucose co-transporter 2 inhibitors can effectively reduce the risk of re-hospitalization and cardiovascular death in patients with or without diabetes, which has a landmark significance for the treatment of heart failure. This article will mainly discuss the latest mechanism of sodium glucose co-transporter 2 inhibitors in the treatment of heart failure.